Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo acquired 353 shares of the business’s stock in a transaction on Monday, October 22nd. The stock was acquired at an average cost of GBX 754 ($9.85) per share, with a total value of £2,661.62 ($3,477.88).

Lorenzo Tallarigo also recently made the following trade(s):

  • On Monday, September 24th, Lorenzo Tallarigo acquired 291 shares of Oxford BioMedica stock. The stock was acquired at an average cost of GBX 913 ($11.93) per share, with a total value of £2,656.83 ($3,471.62).
  • On Wednesday, August 22nd, Lorenzo Tallarigo acquired 302 shares of Oxford BioMedica stock. The stock was acquired at an average cost of GBX 881 ($11.51) per share, with a total value of £2,660.62 ($3,476.57).

LON OXB opened at GBX 753.30 ($9.84) on Tuesday. Oxford BioMedica plc has a 12-month low of GBX 4.44 ($0.06) and a 12-month high of GBX 13.19 ($0.17).

Separately, Peel Hunt reissued a “buy” rating on shares of Oxford BioMedica in a report on Wednesday, October 3rd.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Read More: Stock Split

Insider Buying and Selling by Quarter for Oxford BioMedica (LON:OXB)

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.